Skip to main content

Table 3 Patient and treatment characteristics by high-risk cohort

From: Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Characteristic All patients (n = 547) FHR (n = 225) UHR (n = 92) vHigh Risk (n = 126) FHR vs. UHR p-value
  %   %   %   %
Age (years)
 Median 67.0   67.4   68.4   67.2   278
 Range 46–83   47–83   46–80   48–81   
T Stage (no.) <.0005
 T1b–T2a 132 24 78 35 10 11 0 0  
 T2b–T2c 121 22 51 23 10 11 0 0  
 T3a 168 31 96 43 72 78 0 0  
 T3b-T4 126 23 0 0 0 0 126 100  
PSA (μg/L) <.0005
 Median 14.5   14.1   22.5   14.9   
 Mean 20.2   18.3   31.2   21.9   
 Range 0.6–263   0.6–69   1.8–263   1.2–127   
PSA Group (no.) <.0005
 < 10 μg/L (no.)   28   33   17 37 29  
 10–20 μg/L 151 38 74 34 16 10 44 35  
 (no.) 209 34 76 33 9 73 45 36  
 ≥ 20 μg/L (no.) 187   75   67     
Gleason Score (No.) <.0005
 <7 147 27 80 36 11 12 50 40  
 =7 250 46 91 40 24 26 37 29  
 >7 150 27 54 24 57 62 39 31  
Radiation dose
 Median (Gy) 74.0   74.0   74.0   70.0   .082
Radiation technique .123
 3D–CRT 432 79 170 76 61 66 112 89  
 IMRT 115 21 55 24 31 34 14 11  
Duration of ADT
 Median (months) 8.0   8.0   13.5   8.0   .102
 Mean (months) 14.9   16.4   20.8   13.7   
 Range (months) 0–72   0–53   4–72   0–68   
Duration of ADT (no)
 None (no.) 11 2 4 2 0 0 1 1  
 1–6 months (no.) 181 32 69 31 24 26 44 35  
 7–12 months (no.) 195 34 74 33 22 24 50 40  
 13–24 months (no.) 10 2 3 1 4 4 2 2  
 >24 months (no.) 150 29 75 33 42 46 29 23  
  1. Abbreviations: FHR favourable high risk, UHR unfavourable high risk, PSA prostate-specific antigen, ADT androgen deprivation therapy, 3D–CRT three dimensional conformal radiotherapy, IMRT intensity-modulated radiation therapy